Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

Core Insights - Novo Nordisk plans to invest 8.5 billion Danish kroner to establish a new production facility in Odense, Denmark, marking its first new production site in the country this century [1]. Group 1: Investment and Facility Details - The new facility will cover over 40,000 m² and will be designed to be modular and flexible, accommodating multiple product types for rare diseases, including haemophilia [4]. - Construction has already begun and is expected to be completed by 2027, creating 400 permanent jobs and employing up to 1,000 external workers during the construction phase [6]. Group 2: Environmental Commitment - The facility will incorporate sustainable practices, including the planting of over 4,000 new trees, installation of solar panels for on-site electricity generation, and the reuse of excess materials to create community spaces [5]. Group 3: Company Background - Novo Nordisk is a leading global healthcare company, founded in 1923, with a focus on chronic diseases, particularly diabetes, and operates manufacturing sites in several countries including Denmark, the US, France, Brazil, and China [8][9].